(Q38240747)

31 August 2017

title

LDL cholesterol: controversies and future therapeutic directions (English)

1 reference

31 August 2017

1

Paul M Ridker

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

384

1 reference

31 August 2017

issue

9943

1 reference

31 August 2017

page(s)

607-617

1 reference

Lipoprotein disorders and cardiovascular risk

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

1 reference

7 January 2021

The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

PCSK9: a convertase that coordinates LDL catabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Application of new cholesterol guidelines to a population-based sample

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Agreement Between Fasting and Postprandial LDL Cholesterol Measured with 3 Methods in Patients with Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

What is the role of the clinical laboratory in the new ACC/AHA guidelines for the treatment of blood cholesterol in adults?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Limitations of direct methods and the reference method for measuring HDL and LDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effect of two intensive statin regimens on progression of coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

A trial-based approach to statin guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Screening for future cardiovascular disease using age alone compared with multiple risk factors and age

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Mechanisms for the anti-inflammatory effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Bariatric surgery versus conventional medical therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Bariatric surgery and long-term cardiovascular events.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effects of extended-release niacin with laropiprant in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

n-3 fatty acids and cardiovascular events after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

n-3 fatty acids in patients with multiple cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Simvastatin with or without ezetimibe in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effects of dalcetrapib in patients with a recent acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Future of cholesteryl ester transfer protein inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Lomitapide for homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

The biology and therapeutic targeting of the proprotein convertases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Sub

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled,

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Discovery and refinement of loci associated with lipid levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Anti-inflammatory therapies for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

Anti-inflammatory therapy in chronic disease: challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961009-6

7 January 2021

10.1016/S0140-6736(14)61009-6

Identifiers

DOI

1 reference

31 August 2017

1 reference